HEALTHY EXTRACTS INC.
2.0100-0.22 (-9.87%)
Oct 28, 4:00:00 PM EDT · OTC Markets OTCQB · HYEX · USD
Key Stats
Market Cap
33.91MP/E (TTM)
-Basic EPS (TTM)
-0.14Dividend Yield
0%Recent Filings
8-K
Gummy USA merger finalized
Healthy Extracts Inc. completed its acquisition of Gummy USA LLC via merger on September 30, 2025, after rescinding an initial July purchase agreement. The deal issued 13,075,920 common shares to founder Donald Swanson, granting him 77.5% ownership plus anti-dilution rights against 154,306 options and warrants. Swanson steps in as CEO and Chairman, bringing gummy manufacturing expertise to bolster production capabilities. Leadership shuffled smoothly, yet integration details remain pending.
10-Q
Q2 FY2025 results
Healthy Extracts posted revenue of $968,656 for Q2 ended June 30, 2025, up 7% y/y from $908,389, with gross profit climbing 22% to $592,827 on a 39% margin versus 46% last year, thanks to efficiencies in the BergaMet health supplements segment. Yet operating expenses jumped 40% to $698,434, driven by higher advertising and consulting, yielding a slim $67,120 net income—down from $113,500—while YTD net loss narrowed to $331,739 from $747,758, or $(0.11) per diluted share on 3,050,879 shares, reconciling cleanly. Cash rose to $200,495, with $77,237 operating cash flow (derived) and $30,539 from financing, against $635,687 total debt including $247,423 convertible notes; free cash flow not disclosed in the 10-Q. Post-quarter, the firm closed a July 2025 acquisition of Gummy USA for 13,075,920 shares, recognizing no new goodwill per filing. Revenue growth persists.
8-K
Acquires Gummy USA, leadership shifts
Healthy Extracts Inc. acquired Gummy USA LLC on July 19, 2025, issuing 13,075,920 common shares—77.5% of its post-deal outstanding stock—to founder Donald Swanson, who became Chairman and President while prior President Kevin Pitts shifted to CEO. This deal hands control to Swanson, injecting his gummy supplement manufacturing expertise into the fold. Leadership realigns swiftly. Yet financials remain pending.
10-Q
Q1 FY2025 results
Healthy Extracts kicked off 2025 with revenue surging 35% year-over-year to $931K for the quarter ended March 31, outpacing last year's $689K, while gross profit edged up 4% to $425K on a 54% margin—higher costs squeezed it from 59%. Operating expenses climbed 13% to $534K, mainly from ramped-up advertising that fueled sales, yielding an operating loss of $109K, improved from $62K last year. Yet net loss narrowed to $399K or $0.13 per share from $861K or $0.30, thanks to a milder $255K hit from derivative fair-value changes versus $757K prior. Cash rose to $119K with $60K positive operating flow, but financing outflows trimmed it; total debt sits at $881K including convertibles, with $881K derivative liabilities. Revenue growth shows traction. Derivative volatility poses risks.
10-K
FY2024 results
Healthy Extracts Inc. posted FY2024 revenue of $3.1M, up 25% y/y from $2.5M in 2023, driven by steady demand for its BergaMet heart health and UBN brain supplements amid a stabilizing nutraceuticals market. Gross profit climbed 54% to $1.9M, with margins expanding to 61% from 65%, reflecting efficient inventory management that trimmed stock by $265K year-over-year. Yet operating expenses dropped 46% to $2.1M, mainly from lower stock-based compensation, narrowing the net loss to $841K from $2.5M—Q4 momentum showed sequential revenue gains via e-commerce and influencer channels like Whitney Johns. Cash flow turned positive at $282K, bolstering liquidity to $112K despite $531K in convertible debt; no dividends or buybacks occurred, with capex minimal. No annual guidance disclosed. Intense competition from larger players could erode quarterly gains.
IPO
Employees
Sector
Industry
BIOE
Bio Essence Corp.
0.07+0.00
BSPK
Bespoke Extracts, Inc.
0.25+0.00
CVSI
CV Sciences, Inc.
0.03-0.01
EDXC
ENDEXX Corp.
0.00-0.00
HSTI
High Sierra Technologies Inc.
1.40+0.00
NTRR
Neutra Corp.
0.00+0.00
NXEN
Nexien BioPharma, Inc.
0.01+0.00
NXGB
NxGen Brands Inc.
0.00-0.00
PHBI
Pharmagreen Biotech Inc.
0.00+0.00
PLSH
PANACEA LIFE SCIENCES HLDGS INC
0.07+0.00